Fat Building Up Inside Muscle in Type 1 Diabetes: What Scientists Are Learning

Myosteatosis is the medical term for abnormal buildup of fat inside and between skeletal muscle fibers. While this condition is well recognized in aging, obesity, and cancer, scientists are only now systematically investigating its role in Type 1 diabetes.

The relevance is important because myosteatosis can degrade muscle quality and flexibility—the ability of muscles to switch between different energy sources. It may also contribute to poor metabolic outcomes, even when muscle size appears normal to the eye.

Type 1 diabetes involves three ongoing metabolic stressors: lifelong insulin deficiency, persistent autoimmune activation (the body's immune system attacking the insulin-producing cells), and glycemic variability (fluctuating blood sugar). Together, these profoundly disrupt how muscle cells produce and use energy.

Even in people with Type 1 diabetes who maintain healthy weight and muscle mass, the chronic lack of insulin and ongoing immune activation can push muscle cells toward accumulating fat rather than burning it efficiently.

At the heart of myosteatosis in Type 1 diabetes is dysfunction in a series of molecular switches and pathways that normally keep muscle cells metabolically healthy. The two most important are AMPK (adenosine monophosphate-activated protein kinase) and PPAR (peroxisome proliferator-activated receptor), which work together to coordinate how cells burn fat, build new mitochondria, and maintain energy efficiency.

In Type 1 diabetes, chronic immune stress and metabolic strain suppress both AMPK and PPAR signaling. This dampens the activity of PGC-1α, a master regulator of mitochondrial function. The result: muscle cells lose their capacity to oxidize (burn) fat, and lipids accumulate instead.

Myosteatosis in Type 1 diabetes is further driven by persistent inflammatory signaling. Immune messengers like IL-6, TNF-α, and IL-1β remain elevated, activating inflammatory pathways (NF-κB, JNK, and NLRP3) inside muscle tissue.

Additionally, toxic fat intermediates—particularly ceramides and diacylglycerols—accumulate in the muscle. These compounds interfere with normal cellular signaling and worsen insulin resistance, creating a vicious cycle.

By mapping these immunometabolic pathways, researchers are identifying potential therapeutic targets. The goal is not to reverse Type 1 diabetes itself, but to preserve muscle quality and metabolic flexibility in people living with the condition.

Improved biomarkers and imaging techniques may soon help clinicians detect myosteatosis earlier, while understanding the molecular mechanisms opens doors to treatments targeting the AMPK-PPAR-mitochondrial axis, inflammatory signaling, and lipid metabolism.

Source: Frontiers in endocrinology. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.